Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Treating HAP/VAP in critically ill patients

This promotional meeting is organised and funded by Pfizer and may include reference to Pfizer medicines relevant to agenda topics.

  • Bacterial Topic

Treating HAP/VAP in critically ill patients

Date:  10th November and 12th November

Time: 12pm - 10th November
            6pm - 12th November

Duration: 1 hour 

Additional details: This is a live webinar. A live Q&A with the speaker will be available.

Register Here

About the webinar

This webinar is a promotional event that will focus on:
•    Identification of risk factors and using local epidemiology patterns to enable early adequate therapy
•    The predominant pathogens in patients with HAP/VAP 
•    Overview of REPROVE trial and RWD on efficacy and safety of Zavicefta® (ceftazidime avibactam) in HAP/VAP
•    The importance of early adequate therapy in ICU

About the speaker

Professor Antonio Torres Martí
Professor of Medicine & Head of Respiratory Intensive Care Unit, 
Hospital Clinic of Barcelona. University of Barcelona

This meeting is organised & funded by Pfizer Ltd. Please note that, under the law and the ABPI Code of Practice, Pfizer may only promote its medicines and provide hospitality to members of the healthcare professions and other relevant decision makers. Therefore, no unqualified person (e.g. medical students, non-medical spouses/partners/family members) may be invited to or attend Pfizer promotional meetings. 


Prescribing information

Zavicefta (ceftazidime avibactam)
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion – SPC
Legal category: POM. Basic NHS price: 10 vial pack £857.00.